Trial Profile
Setmelanotide (RM-493) Treatment Trial in Patients with rare genetic disorders of obesity
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Setmelanotide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- 23 Mar 2021 Results from NCT02507492, NCT02896192 and NCT03287960 evaluating onset of adverse events in patients with POMC/PCSK1 or LEPR deficiency obesity treated with setmelanotide, presented at the 103rd Annual Meeting of the Endocrine Society
- 09 Mar 2021 According to a Rhythm Pharmaceuticals media release, data from this study will be presented by Karine Clement at the 103rd Annual Meeting and Expo of the Endocrine Society (ENDO 2021).
- 15 Jan 2021 Status changed from recruiting to completed.